Screener
PTC Therapeutics PTCT Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001070081-26-000012
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $833,986 | $984,648 |
| Marketable securities | 1,058,477 | 960,723 |
| Trade and royalty receivables, net | 219,919 | 181,621 |
| Inventory, net | 75,567 | 79,647 |
| Prepaid expenses and other current assets | 66,054 | 67,309 |
| Total current assets | 2,254,003 | 2,273,948 |
Item 1. Financial Statements (unaudited)
FAQ
- What is PTC Therapeutics's cash & equivalents?
- PTC Therapeutics (PTCT) reported cash & equivalents of $833.99M in Q1 2026.
- How has PTC Therapeutics's cash & equivalents changed year-over-year?
- PTC Therapeutics's cash & equivalents decreased by 43.7% year-over-year, from $1.48B to $833.99M.
- What is the long-term trend for PTC Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), PTC Therapeutics's cash & equivalents has grown at a 36.4% compound annual growth rate (CAGR), from $208.81M to $984.65M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about PTC Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude